Alamar Biosciences and the German Center for Neurodegenerative Diseases (DZNE) partner for Landmark Proteomic Profiling study in the Rhineland Study Cohort
FREMONT, Calif., July 29, 2025 /CNW/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, today announced a strategic collaboration with the German Center for Neurodegenerative Diseases (DZNE) to deploy its ultra-sensitive NULISAseq™ CNS Disease Panel 120 and Inflammation Panel 250 in the Rhineland Study—one of the world's most comprehensive and innovative longitudinal aging cohorts, as well as in some of the DZNE's clinical disease specific cohorts. This initiative will profile 23,000 plasma samples to accelerate biomarker discovery and advance understanding of healthy aging and neurodegeneration.
"Understanding aging and dementia requires both advanced technology and deeply characterized cohorts," said Prof. Monique Breteler, Director of Population Health Sciences at DZNE and Principal Investigator of the Rhineland Study. "Integrating Alamar's multiplex panels into our research opens new opportunities to decode the molecular signatures of brain aging."
The DZNE Rhineland Study is an ongoing, large-scale population-based cohort designed to investigate determinants of healthy aging and the development of neurodegenerative diseases across the lifespan. By utilizing Alamar's NULISAseq CNS Disease Panel 120, researchers will be able to measure hundreds of brain-related proteins from minimal blood volumes, with exceptional sensitivity and specificity. Notably, the CNS panel's ability to distinguish brain-derived phosphorylated tau from total phosphorylated tau in plasma represents a transformative advance for early detection and risk stratification of neurodegenerative conditions such as Alzheimer's disease. In addition, the NULISAseq Inflammation Panel 250 provides the most comprehensive and sensitive profiling of immune-related proteins implicated in aging and neuroinflammation associated with neurodegenerative diseases.
The resulting proteomic data will be combined with the study's extensive clinical, demographic, and imaging datasets, enabling researchers to track protein changes over time, identify early biomarkers, and support the development of precision diagnostics and targeted therapies.
"This partnership marks a major step forward in aging and dementia research," said Yuling Luo, PhD, Founder, Chairman and CEO of Alamar Biosciences. "With NULISA's unmatched sensitivity and the depth of the DZNE Rhineland Study, we can uncover novel protein biomarkers that reveal the trajectories of cognitive health and disease progression in aging populations."
This collaboration reflects a shared commitment to scientific rigor, inclusivity, and innovation in neurodegenerative disease research. By capturing diverse aging trajectories in a deeply characterized population, Alamar and DZNE aim to drive earlier diagnosis, improved prognosis, and new therapeutic pathways for age-related brain disorders.
About the DZNE Rhineland Study
The DZNE (German Center for Neurodegenerative Diseases) Rhineland Study is an ambitious, population-based cohort following thousands of individuals across decades to uncover determinants of healthy aging and neurodegeneration. Detailed clinical, imaging, genetic, and lifestyle data are collected and harmonized to enable deep insights into the aging brain. Learn more about the DZNE at www.dzne.de/en/, and about the DZNE Rhineland Study at www.rheinland-studie.de/en/
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company with a mission to power precision proteomics to enable the earliest detection of disease. The company's proprietary NULISA Platform along with the ARGO HT System work seamlessly with the latest advances in genomics to achieve single digit attomolar detection sensitivity, greatly surpassing the most sensitive protein detection technology on the market today. For more information, please visit alamarbio.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Toronto Star
2 days ago
- Toronto Star
PharmAla Delivers MDMA to Merhavim Mental Health Centre Clinical Trial in Exchange for Full Data License
TORONTO, Aug. 07, 2025 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. ('PharmAla' or the 'Company') (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce that it has completed customs clearance and delivery of over 500 capsules of the company's LaNeo 40mg MDMA to Merhavim Mental Health Centre of Beer Yaakov, Israel ('Merhavim'). 'We believe that this delivery sets a precedent in terms of the innovative terms agreed-to with Merhavim – terms that allows researchers to explore new and complex mental health indications with less financial risk while allowing PharmAla to develop important intellectual property in a cost-effective manner,' said Nick Kadysh, CEO of PharmAla Biotech. 'However it also continues to show PharmAla's ability to work rapidly on behalf of our clients, with just 6 months between execution and delivery of the shipment – even with complexity in not only cross-border trade and tariff pressure, but also a significant conflict in the region.'
Cision Canada
2 days ago
- Cision Canada
iGan Partners Invests in DOCSI to Transform Surgical Supply Chain Optimization
TORONTO, Aug. 7, 2025 /CNW/ - iGan Partners ( is pleased to announce its investment in DOCSI ( a Minneapolis-based company revolutionizing perioperative supply chain management through its mobile-first surgical preference dashboard. DOCSI helps hospitals and surgery centers digitize preference-card workflows, engage surgeons more effectively, and reduce supply costs — all without complex IT integrations. Its simple, data-driven platform is already used by large health networks, including Allina Health, to cut waste, standardize supplies, and drive savings. "At iGan Partners, we invest in solutions that deliver practical, measurable impact," said Sam Ifergan, Founder and Managing Partner at iGan Partners. "DOCSI's scalable platform aligns perfectly with our mission to modernize critical healthcare workflows—lowering costs, reducing variation, and empowering clinicians." "We're thrilled to welcome iGan Partners as a strategic investor," said Andrew DeLeeuw, CEO of DOCSI. "Their deep expertise in scaling healthcare technology companies will help us accelerate our mission to eliminate surgical waste, improve physician engagement, and simplify supply chain decisions for health systems." This investment reflects iGan's commitment to supporting entrepreneurs who are disrupting healthcare and driving meaningful improvements across the industry. About DOCSI Based in Minnesota, DOCSI is a surgeon-founded technology company that helps hospitals and surgery centers optimize supply chain efficiency by digitizing preference-card management and enhancing surgeon engagement. Its Surgical Preference Dashboard™ makes it easy to identify opportunities to reduce costs, standardize care, and limit waste with minimal IT burden. About iGan Partners iGan Partners is a North American venture capital firm focused on driving meaningful change in healthcare through investments in early- and growth-stage companies. We partner with visionary entrepreneurs who are building enterprise technologies to improve patient outcomes, increase operational efficiency, and deliver systemic transformation.
Cision Canada
4 days ago
- Cision Canada
Seegene Unveils CURECA™ and STAgora™ at ADLM 2025, Advancing the Next Stage of Diagnostics
Dr. , Chairman and CEO of Seegene, highlights progress toward fully automated and data-driven molecular testing Introduction of CURECA™, the first fully unattended PCR automation system, and STAgora™, a real-time global data analytics platform Technologies designed to scale automation, enhance data insights, and support the company's long-term vision of a world free from diseases SEOUL, South Korea, Aug. 5, 2025 /CNW/ -- Seegene Inc., a global leader in molecular diagnostics, unveiled two new technologies at ADLM 2025 in Chicago (July 29–31) designed to advance laboratory automation and data-driven infectious disease monitoring. The company introduced CURECA™, world's first fully unattended PCR automation system, and STAgora™, a real-time data analytics platform intended to support earlier detection and precision care. Chairman Highlights Next Step in Molecular Diagnostics "With CURECA™ and STAgora™, we are taking an important step toward the future of diagnostics," said Dr. Jong-Yoon Chun, Chairman and CEO of Seegene, during a press conference with U.S. and global media on July 30. "Our goal is to enable laboratories worldwide to automate complex testing workflows and use diagnostic data more effectively, ultimately helping advance global efforts toward a world free from diseases." Today, most molecular testing systems remain only partially automated, dependent on skilled personnel for repetitive manual steps and fixed workflows that limit efficiency and scalability. CURECA™ Breaks the Limits of Automation to Reshape Global Diagnostics CURECA™ is the first system in the diagnostics industry designed to fully automate every step of PCR testing, including the traditionally manual pre-treatment stage. Seegene notes that achieving true full automation in diagnostics requires three key conditions: operation without highly trained professionals, continuous 24-hour processing, and uninterrupted specimen input. CURECA™ is designed to meet all three. Its dedicated module, CURECA™ Prep, processes a wide range of specimen types such as urine, blood, sputum, and stool, addressing one of the most persistent barriers to automation. With the module handling diverse specimen pre-treatment, the full CURECA™ system completes the entire PCR workflow from sample loading through nucleic acid extraction, amplification, and result analysis without manual intervention. The system is engineered for continuous 24-hour operation, aiming to minimize human error, improve workflow efficiency, and allow laboratories to allocate skilled staff to higher-value activities. Full automation has long been a challenge in diagnostics due to specimen variability and the reliance on trained personnel for repetitive pre-processing tasks. CURECA™ is intended to help laboratories overcome these constraints by providing a scalable and adaptable system that can be configured to fit different lab sizes and workflows. CURECA™ Prep could also potentially extend to other testing fields, such as clinical chemistry and immunodiagnostics, as Seegene continues to explore broader automation solutions. STAgora™ Transforms Diagnostic Data into Real-Time Clinical Intelligence STAgora™ is Seegene's latest platform, designed to collect and analyze PCR testing data in real time, providing laboratories with broader context to inform diagnostic workflows. The platform includes more than 40 analytical tools, offering functions such as infection trend tracking, hospital-level positivity monitoring, and multi-pathogen co-infection pattern analysis. Rather than serving as a simple data repository, STAgora™ is built as an integrated platform intended to help laboratories derive meaningful, aggregated insights from testing data. Today, individual test results often provide limited information without broader reference points. STAgora™ is designed to address this by enabling hospitals to build their own statistical datasets and compare aggregated data across institutions, helping them detect infection patterns faster and support more informed decision-making. The data shared through the platform is de-identified and formatted according to each institution's requirements, supporting secure, real-time exchange at local, national, or global levels. Advancing Toward a World Free from All Diseases Dr. Chun reiterated Seegene's long-term vision of building "a world free from diseases" noting that the introduction of CURECA™ and STAgora™ completes the company's five core technology pillars. These include Seegene's proprietary PCR technology, the SGDDS (Seegene Digitalized Development System) for automated assay development, its global Technology-Sharing Initiative, and now the addition of fully automated PCR testing and real-time data analytics capabilities. Industry experts at ADLM 2025 expressed strong interest in Seegene's new technologies. Jamel Giuma, President and CEO of Miami based laboratory IT consulting firm JTG Consulting Group, said, "I've attended many ADLM conferences over the years, and CURECA™ is one of the most innovative solutions I have seen so far. I believe it has the potential to simplify laboratory workflows, reduce the burden on lab personnel, and greatly enhance overall operational efficiency." "With CURECA™ and STAgora™, we're addressing long-standing barriers in molecular diagnostics," Dr. Chun added. "Just as smartphones and electric vehicles transformed their industries, we believe these technologies will redefine what is possible in diagnostic testing, helping laboratories worldwide achieve true automation, unlock the value of diagnostic data, and ultimately contribute to building a world free from diseases." Disclaimer CURECA™ and STAgora™ demonstrated at ADLM 2025 are pre-commercial technologies under development, not commercially available, and are not currently cleared for clinical diagnostic use in any jurisdiction.
